Skip to main content
Przejdź do strony domowej Komisji Europejskiej (odnośnik otworzy się w nowym oknie)
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS

Transfer of multivirus-specific T-cells following transplantation

CORDIS oferuje możliwość skorzystania z odnośników do publicznie dostępnych publikacji i rezultatów projektów realizowanych w ramach programów ramowych HORYZONT.

Odnośniki do rezultatów i publikacji związanych z poszczególnymi projektami 7PR, a także odnośniki do niektórych konkretnych kategorii wyników, takich jak zbiory danych i oprogramowanie, są dynamicznie pobierane z systemu OpenAIRE .

Rezultaty

Site selection (odnośnik otworzy się w nowym oknie)

Site feasibility assessment and final site selection and contracts are needed for approximately 20-25 sites (3rd party as subcontractors). LMU will coordinate the site selection and will set up a contact office for all clinical and regulatory questions raised by physicians that treat patients or may have candidates for an inclusion into this clinical trial. LMU, OPBG, LUMC, CHU, UNEW and UZG will select the clinical sites for recruitment of patients in their Country.

Plan for the analysis of the functional activity of the multivirus-specific T cell product (odnośnik otworzy się w nowym oknie)

Therefore, the functional activity of T cells specific for immunodominant epitopes derived from different proteins of the targeted viruses (e.g. CMV, EBV, and AdV) presented by different HLA alleles will be determined. On target (anti-viral) reactivity of the isolated T-cell products will be analysed upon stimulation with peptides/peptide pools of the different viral antigens, and functional reactivity will be assessed by flow cytometry using counterstaining with CD4/8 antibodies and staining for specific activation markers (CD137, CD154) and relevant cytokines (IFNγ, IL-4, GM-CSF).

Approval of >12 study sites (Package 2) (odnośnik otworzy się w nowym oknie)

A second approval package will contain all approvals from ethics committees and national competent authorities from more than 12 study sites once the last approval has been received.

Registration number of clinical study in a WHO- or ICMJE-approved registry (odnośnik otworzy się w nowym oknie)

The clinical trial documents will be submitted to the competent authorities and the ethical review boards. The partners LMU, OPBG, LUMC, CHU, UNEW, UZG are involved in this task. The task leader LMU will submit the trial to the German competent authority Paul-Ehrlich-Institut. The role of all other participants (OPBG, LUMC, CHU, UNEW, UZG) will be to submit the trial to their national and local authorities.

Individualized press release for every partner (odnośnik otworzy się w nowym oknie)

Patient organisations will be included in a three level approach. Patient organisations will be involved in dissemination (local level), a representative of the national umbrella organisation will be part of the advisory board (national level) and the consortium will be represented at the “Patient and Family Day” of the EBMT (European Group for Blood and Marrow Transplantation).

Final version of study protocol as approved by first regulatory/ethics committee (Package 1) (odnośnik otworzy się w nowym oknie)

The clinical trial documents will be submitted to the competent authorities and the ethical review boards. The partners LMU, OPBG, LUMC, CHU, UNEW, UZG are involved in this task. The task leader LMU will submit the trial to the German competent authority Paul-Ehrlich-Institut. The role of all other participants (OPBG, LUMC, CHU, UNEW, UZG) will be to submit the trial to their national and local authorities. Deliverables D 2.5 and 2.6 are the outcome of this task, which will contain the whole submission package, including the final version of the study protocol as approved by competent authorities.

SOP for immune monitoring of patient samples (odnośnik otworzy się w nowym oknie)

immune monitoring of peripheral blood and bone marrow samples taken from the patients enrolled in the clinical trial described in this proposal are of utmost importance. Blood samples and if possible bone marrow samples will be drawn from the patients before the infusion of the multivirus- specific T-cell product and at different time-points afterwards. The presence of T cells directed against the targeted viruses (e.g. CMV, EBV and AdV) will be analysed by multi-colour flow cytometry using HLA/peptide multimers for known immunodominant viral epitopes combined with antibodies for different T-cell phenotypes (central memory, effector memory, memory stem T cells or effector T cells). Also restimulation experiments with viral peptide pools, followed by counterstaining with CD4/8 antibodies and staining for specific activation markers (CD137, CD154) and/or relevant cytokines (IFNγ, IL-4, GM-CSF) will be used.

Launch of website and social media account (odnośnik otworzy się w nowym oknie)

LMU will set up and perform maintenance of the consortium homepage and social media accounts such as LinkedIn, Facebook or Twitter dependent on the preference of patient organisations. All participants of the consortium will provide information for the website.

Publikacje

CRISPR-Cas9-Mediated Glucocorticoid Resistance in Virus-Specific T Cells for Adoptive T Cell Therapy Posttransplantation (odnośnik otworzy się w nowym oknie)

Autorzy: Theresa Kaeuferle, Larissa Deisenberger, Lena Jablonowski, Tanja A. Stief, Franziska Blaeschke, Semjon Willier, Tobias Feuchtinger
Opublikowane w: Molecular Therapy, Numer 28, 2025, Strona(/y) 1965-1973, ISSN 1525-0016
Wydawca: Nature Publishing Group
DOI: 10.1016/j.ymthe.2020.06.002

Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections (odnośnik otworzy się w nowym oknie)

Autorzy: Tanja A. Stief, Theresa Kaeuferle, Thomas R. Müller, Michaela Döring, Lena M. Jablonowski, Kilian Schober, Judith Feucht, Kevin M. Dennehy, Semjon Willier, Franziska Blaeschke, Rupert Handgretinger, Peter Lang, Dirk H. Busch, Tobias Feuchtinger
Opublikowane w: Molecular Therapy, Numer 30, 2025, Strona(/y) 198-208, ISSN 1525-0016
Wydawca: Nature Publishing Group
DOI: 10.1016/j.ymthe.2021.05.021

Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation (odnośnik otworzy się w nowym oknie)

Autorzy: Theresa Kaeuferle, Ramona Krauss, Franziska Blaeschke, Semjon Willier, Tobias Feuchtinger
Opublikowane w: Journal of Hematology & Oncology, Numer 12/1, 2019, Strona(/y) 12-13, ISSN 1756-8722
Wydawca: BioMed Central
DOI: 10.1186/s13045-019-0701-1

Genome‐wide off‐target analyses of CRISPR/Cas9‐mediated T‐cell receptor engineering in primary human T cells (odnośnik otworzy się w nowym oknie)

Autorzy: Theresa Kaeuferle, Tanja A Stief, Stefan Canzar, Nayad N Kutlu, Semjon Willier, Dana Stenger, Paulina Ferrada‐Ernst, Nicola Habjan, Annika E Peters, Dirk H Busch, Tobias Feuchtinger
Opublikowane w: Clinical & Translational Immunology, Numer 11, 2023, ISSN 2050-0068
Wydawca: Wiley
DOI: 10.1002/cti2.1372

Guiding Antiviral Cell Therapy Approaches with an Online Resource of Clinically Scored Epitopes, T-Cell Receptors, and B-Cell Receptors (odnośnik otworzy się w nowym oknie)

Autorzy: Theresa Kaeuferle, Britta Eiz-Vesper, Andreas Moosmann, Uta Behrends, Michel Decker, Lilli Gutjahr, Josef Mautner, Florian Klein, Christoph Kreer, Mira Reger, Dirk H. Busch, Elvira D’Ippolito, Florian Kohlmayer, Amrei Menzel, Semjon Willier, Britta Maecker-Kolhoff, Tobias Feuchtinger
Opublikowane w: Transfusion Medicine and Hemotherapy, 2025, Strona(/y) 1-9, ISSN 1660-3796
Wydawca: S. Karger AG
DOI: 10.1159/000548312

Wyszukiwanie danych OpenAIRE...

Podczas wyszukiwania danych OpenAIRE wystąpił błąd

Brak wyników

Moja broszura 0 0